文献速递外周动脉疾病主动脉疾病

TASC C和D型主髂动脉闭塞性疾病应用膨体聚四氟乙烯覆膜支架腔内治疗的长期结果

Long-term Results of Endovascular Treatment of TASC C and D Aortoiliac Occlusive Disease with Expanded Polytetrafluoroethylene Stent Graft.
PubMed 文献 · Ann Vasc Surg · 2018-10-17

回顾性分析2个大学医学中心2006年1月至2017年11月61例TASC II C和D型主髂动脉闭塞性疾病患者,采用VIABAHN覆膜支架腔内治疗。技术成功率96.7%,围手术期死亡率1.6%,36个月一期通畅率94.9%,作者认为该治疗可行、有效且长期通畅率良好。

要点

  • 61例TASC C/D型主髂动脉病变患者,技术成功率96.7%(59/61)。
  • 围手术期死亡率1.6%,术后主要并发症2例(3.6%)。
  • 平均随访31.5个月,36个月一期通畅率94.9%。

核心结论

  • 作者认为使用VIABAHN覆膜支架对TASC C和D型髂动脉病变行腔内治疗可行、有效,且长期通畅率良好。

研究设计与样本

  • 回顾性分析2006年1月至2017年11月在2个大学医学中心接受VIABAHN覆膜支架治疗的61例(男53例,女8例)有症状主髂动脉狭窄和/或闭塞性疾病患者。
  • 病变形态通过对比增强计算机断层扫描血管造影评估并分类,随访数据采用寿命表分析(Kaplan-Meier检验)分析。

主要发现

  • 患者平均年龄64.89±10.77岁(范围44-89)。
  • 37例(60.7%)为严重跛行(Rutherford 3级),21例(34.4%)为Rutherford 4级,其余3例(4.9%)为坏死性病变(Rutherford 5/6级)。
  • 技术成功率为59/61例(96.7%),其中16例(26.2%)需要联合经肱动脉入路以获得髂动脉再通。
  • 围手术期死亡率为1.6%,术后主要并发症发生于2例患者(3.6%);平均置入VIABAHN支架1.77个/患者。
  • 平均随访31.5个月(范围1-108),36个月一期通畅率为94.9%;随访期间发生2例下肢主要截肢。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study is to retrospectively analyze the early and long-term outcomes of endovascular treatment of Trans-Atlantic Inter-Society Consensus II class C and D (TASC II) aortoiliac occlusive disease with an expanded polytetrafluoroethylene-covered stent graft. METHODS: Between January 2006 and November 2017, 61 patients (53 males, 8 females), with symptomatic aortoiliac stenotic and/or occlusive disease, were treated with VIABAHN (W.L. Gore and Associates, Flagstaff, Ariz) at 2 University medical centers. The morphology of the lesions was evaluated and classified by contrast-enhanced computed tomography angiography. Demographic data, operation details, and postoperative outcomes were collected. Follow-up data were analyzed by a life-table analysis (Kaplan-Meier test). RESULTS: Mean age of the patients was 64.89 ± 10.77 years (range 44-89). Thirty-seven patients (60.7%) presented with severe claudication (Rutherford 3), whereas 21 (34.4%) were in Rutherford class 4 and the remaining 3 patients (4.9%) suffered from necrotic lesions (Rutherford 5/6). Fifty-six patients were smokers (91.8%), 38 (62.3%) had hypertension, 23 (37.7%) had coronary artery disease, 30 (40.2%) had dyslipidemia, 18 (29.5%) had chronic obstructive pulmonary disease, 6 (9.5%) had renal insufficiency (serum creatinine>2.0 mg/dL) and 24 (39.3%) had diabetes. Technical success was achieved in 59/61 patients (96.7%) with 16 patients (26.2%) requiring combined percutaneous brachial access to obtain iliac recanalization. Perioperative mortality was 1.6%, whereas postoperative major complications occurred in 2 patients (3.6%). The mean number of VIABAHN placed was 1.77/patient. Mean follow-up was 31.5 months (range 1-108) and primary patency at 36 months was 94.9%. Two major amputations of the lower limbs occurred during the follow-up. CONCLUSIONS: Open surgery with the aortobifemoral bypass has been the gold standard treatment for complex aortoiliac occlusive disease although complications and mortality still remain significant issues. Our results suggest that endovascular therapy of TASC C and D iliac lesions using the VIABAHN stent graft is feasible, effective, and has good, long-term patency.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bracale UM, Giribono AM, Spinelli D, et al. Long-term Results of Endovascular Treatment of TASC C and D Aortoiliac Occlusive Disease with Expanded Polytetrafluoroethylene Stent Graft. Ann Vasc Surg. 2018. PMID: 30339903. doi:10.1016/j.avsg.2018.07.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。